Meet Your Lentiviral Vector Development And Supply Requirements With An Optimized Suspension-Based Platform Technology

By Lisa Prendergast, Licensing, and Bingnan Gu, Research & Development

Demand for lentiviral vectors (LVVs) as delivery vehicles for gene therapies is rising significantly, creating a need for robust, highly productive and scalable manufacturing processes. Lonza's ready-to-use, suspension-based Xcite^® Lenti Platform Technology for transient transfection of LVVs eliminates that need to transition from small-scale adherent processes, shortening timelines to GMP production and providing confidence that LVV production processes will be suitable for large-scale manufacturing.